Patients with clinically significant bronchiectasis featuring an eosinophilic inflammatory endotype who were treated with add-on mepolizumab or benralizumab showed a significant improvement of FEV₁, symptom burden and quality of lifehttp://bit.ly/2AZvBLm
No takes yet. Share an insight, caveat, or question.
Rademacher et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: